Oligodendrocyte progenitor cells repair damaged spine in humans in clinical trial...
• http://www.nextbigfuture.comAsterias Biotherapeutics (NYSE: AST) recently announced ground-breaking results restoring function to patients with spinal injuries from a Phase 1 clinical trial that were nothing short of astounding.